Biotech Values

[DewDiligence]

XOMA CC addendum: A Gevokizumab BLA based on EYEGUARD-B only* would have only a Behçet’s indication rather than a general NIU indication. Since the Behçet’s prevalence is many times smaller than the general NIU prevalence, a Behçet’s-only indication would require that Gevokicumab carry a very high price to produce commercially meaningful sales.

*The backup plan mentioned for the first time on today’s CC.